LAVA Therapeutics Announces Selection By Janssen Of Lead Gamma-Delta T-Cell Engager Bispecific Antibody To Move Toward Clinical Development
Portfolio Pulse from Happy Mohamed
LAVA Therapeutics announced that Janssen Biotech, a part of Johnson & Johnson, has chosen a lead candidate for further development towards clinical settings within their research collaboration. The collaboration focuses on the discovery and development of novel bispecific antibody-based gamma delta T cell engagers for cancer treatment.
June 01, 2023 | 8:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson's Janssen Biotech selects a lead candidate from its research collaboration with LAVA Therapeutics for further clinical development in cancer treatment.
The selection of a lead candidate from the research collaboration with LAVA Therapeutics is a positive development for Johnson & Johnson's Janssen Biotech. This progress in cancer treatment research could potentially lead to new products and revenue streams for the company, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
LAVA Therapeutics' collaboration with Janssen Biotech results in the selection of a lead candidate for further clinical development in cancer treatment.
The announcement of a lead candidate from LAVA Therapeutics' research collaboration with Janssen Biotech is a significant milestone for the company. This progress in their cancer treatment research could potentially lead to new products, revenue streams, and increased credibility in the industry, positively impacting LAVA Therapeutics' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100